In a rare television appearance, Cadila Healthcare's relatively new Managing Director, Sharvil Patel spoke with CNBC-TV18's Ekta Batra on a whole host of issues including their hope of becoming India's number one oncology player within the next 5 years.
We have one of the largest pipelines filed with the US Food and Drug Administration (US FDA), said Patel. We have over 50 approvals already in the US, he added.
Patel sees tremendous potential in the US generic space.
Our India business is very stable, he said.
We want to significantly expand emerging market business, he added.
He further said that revenue growth will be driven majorly by the US business.
"We are concentrating on three-four therapy areas mostly in neuropathic pain, oncology, gastrointestinal as well as dermatology. So we would look to acquire some assets in these areas in the US," said Patel.
For full interview, watch accompanying videos...
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
